Met gene amplification and protein hyperactivation is a mechanism of resistance to both first and third generation EGFR inhibitors in lung cancer treatment

Global cancer statistics, 2012

Lindsey A. Torre, Freddie Bray, Rebecca L. Siegel et al. · CA A Cancer Journal for Clinicians · 2015 · 27.4K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

Cancer statistics, 2015

Rebecca L. Siegel, Kimberly D. Miller, Ahmedin Jemal · CA A Cancer Journal for Clinicians · 2015 · 11.9K citations · Full text

Medicine, Oncology, Cancer Epidemiology +16

<i>MET</i> Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling

Jeffrey A. Engelman, Kreshnik Zejnullahu, Tetsuya Mitsudomi et al. · Science · 2007 · 4.5K citations · Full text

Medicine, Oncology, Pharmacology +17

AZD9291 in EGFR Inhibitor–Resistant Non–Small-Cell Lung Cancer

Pasi A. Jänne, James Chih‐Hsin Yang, Dong‐Wan Kim et al. · New England Journal of Medicine · 2015 · 2.1K citations · Full text

Medicine, Oncology, Pharmacology +16

Acquired EGFR C797S mutation mediates resistance to AZD9291 in non–small cell lung cancer harboring EGFR T790M

Kenneth S. Thress, Cloud P. Paweletz, Enriqueta Felip et al. · Nature Medicine · 2015 · 1.5K citations · Full text

Medicine, Molecular Biology, Oncology +11